Abivax CEO Marc de Garidel discusses Obefazimod's phase 3 trial result in ulcerative colitis, and what is next for the company
Jul 24, 2025
26:55
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
He covers the mechanism of action, this week's efficacy and safety data, what it might mean for the maintenance trial that will read out in 2Q26, additional indications, IP, business development, and more.
BiotechTV - News